600211.SH
西藏药业
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 38.16
−2.13%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
9.6x
Market Cap
CNY 12.30B
MomentumView details →
1D Return
−2.13%
YTD Return
−10.55%
RSI (14)
46.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
9.6x
Market Cap
CNY 12.30B
RSI (14)
46.1
MomentumView details →
1D Return
−2.13%
YTD Return
−10.55%
Similar companies
Latest newsMore news →
Tibet Pharmaceutical announced that as of the end of August 2026, it had repurchased 4,000,058 shares of its own stock, representing 1.24% of total shares, for a total amount of 177,595,651.46 yuan.3d agoTibet Rhodiola Pharmaceutical proposed a cash dividend of 1.15 yuan per share (pre-tax) to all shareholders, based on total share capital excluding treasury shares.22d agoTibet Rhodiola Pharmaceutical announced its 2026 half-year results: revenue of 1.554 billion yuan, down 5.83% year-on-year; net profit attributable to shareholders of 608 million yuan, up 7.16% year-on-year; non-recurring net profit of 440 million yuan, down 19.00% year-on-year.22d ago